Modality
Cell Therapy
MOA
Menini
Target
CD20
Pathway
RNA Splicing
GIST
Development Pipeline
Preclinical
~Jul 2016
→ ~Oct 2017
Phase 1
Jan 2018
→ Mar 2029
Phase 1Current
NCT05085762
1,966 pts·GIST
2019-06→2026-11·Not yet recruiting
NCT08923302
1,678 pts·GIST
2018-01→2029-03·Recruiting
3,644 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-11-258mo awayPh2 Data· GIST
2029-03-072.9y awayPh2 Data· GIST
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2
P1/2
Recruit…
P1/2
Not yet…
Catalysts
Ph2 Data
2026-11-25 · 8mo away
GIST
Ph2 Data
2029-03-07 · 2.9y away
GIST
RecruitingNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05085762 | Phase 1/2 | GIST | Not yet recr... | 1966 | 6MWD |
| NCT08923302 | Phase 1/2 | GIST | Recruiting | 1678 | Safety |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Mavutenlimab | Johnson & Johnson | Phase 3 | Cl18.2 | |
| JNJ-8637 | Johnson & Johnson | NDA/BLA | CD20 | |
| Ivorelsin | Eli Lilly | Approved | JAK1 | |
| Lisolucimab | Novartis | Approved | CD20 | |
| ABB-8985 | AbbVie | Phase 2 | CD20 | |
| NVO-2974 | Novo Nordisk | NDA/BLA | PARP | |
| ARG-3265 | Argenx | Phase 1/2 | CD20 | |
| CRS-6525 | CRISPR Therapeutics | Phase 2 | CD20 | |
| Olpafutibatinib | Immunocore | Approved | SMN2 | |
| AKR-4818 | Akero | Approved | CD20 |